BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie's Disease

Links shared publicly online about this topic.

  • 805
    total visits

BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie's Disease

medicalnewstoday.com —

BioSpecifics Technologies Corp. (Nasdaq: BSTC), a biopharmaceutical company developing first in class collagenase-based products, announced that its partner Auxilium Pharmaceuticals, Inc. (Auxili

View full resource at medicalnewstoday.com

Tags: Disease and Condition, Pharma, Phase 3 Clinical Trial, disease

  • Share

Most Recently Shared on October 13, 2010 at 4:05 pm By:

mnt_clinical MNT Clinical Trials

BioSpecifics Technologies Corp. Announces Initiation Of Global Phase 3 Trial Of XIAFLEX® For Treatment Of Peyronie... http://mnt.to/3L7g

2 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Men's Health MNT Men's Health

MNT Sexual Health MNT Sexual Health

MNT Pharma News MNT Pharma News

Advertisement